Business Context and Reporting Period
Company: Quantum-Si Inc (QSI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Quantum-Si is an early-stage life sciences technology company focused on proteomics research. It develops a proprietary, universal, single-molecule detection platform for Next-Generation Protein Sequencing (NGPS). The company commercializes the Platinum and Platinum Pro instruments, along with consumable kits and analysis software. In November 2025, the company updated its roadmap for the next-generation "Proteus" platform, anticipated for launch by the end of 2026.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $2,436 | $3,058 |
| Gross Profit | $1,153 | $1,600 |
| Gross Margin | 47.3% | 52.3% |
| Net Loss | $(101,339) | $(101,007) |
| Operating Cash Flow | $(94,717) | $(87,795) |
| Cash & Marketable Securities (Dec 31, 2025) | $215,800 | $209,603 |
| Accumulated Deficit (Dec 31, 2025) | $(697,980) | $(596,641) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 20.3% to $2.4 million, driven by longer capital sales cycles and budget constraints at academic customers (specifically NIH funding impacts). Product revenue fell 21.8% while service revenue increased 12.8%.
- One-Time Expenses: Operating expenses increased 6.4% primarily due to two significant non-recurring items in 2025:
- Lease Termination Expense: $13.6 million recorded to settle a lease dispute and terminate a facility in New Haven, Connecticut.
- Legal Settlement Expense: $5.2 million recorded for settlements related to Delaware Stockholder Litigation and a former contract manufacturer dispute.
- Equity Financing: The company raised approximately $93.5 million in net proceeds from two registered direct offerings in January and July 2025, significantly bolstering liquidity.
- Warrant Liability Gain: Recognized a $4.2 million non-cash gain due to a decrease in the fair value of warrant liabilities, compared to a $3.7 million loss in 2024.
Guidance, Outlook, and Risks
- Product Roadmap: The company launched the Platinum Pro sequencer in early 2025. The next-generation "Proteus" platform is in development with an anticipated commercial launch by the end of 2026. Proteus aims to offer significantly higher sequencing output and automation.
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($215.8 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring net losses and negative operating cash flows until commercial scale is achieved.
- Key Risks:
- Profitability: History of net losses and negative cash flow; no assurance of future profitability.
- Commercialization: Risk that customers may delay purchases in anticipation of the Proteus launch.
- Regulatory: Products are currently "Research Use Only" (RUO); future clinical applications would require FDA clearance.
- Supply Chain: Reliance on single-source suppliers for critical components and third-party foundries for semiconductor wafers.
- Internal Controls: Past material weaknesses in internal controls over financial reporting, though management concluded controls were effective as of December 31, 2025.
Investor Verification Checklist
- Revenue Sustainability: Verify the extent of the revenue decline and the specific impact of NIH budget cuts on the customer base.
- One-Time Costs: Confirm the finality of the $13.6 million lease termination and $5.2 million legal settlement to ensure no further liabilities exist.
- Proteus Timeline: Assess the technical milestones and risks associated with the end-of-2026 launch of the Proteus platform.
- Capital Runway: Monitor the burn rate relative to the $215.8 million cash position to validate the 12-month liquidity assertion.
- Warrant Liability: Review the fair value assumptions for the outstanding warrants (Public and Private) which expire in June 2026 and impact earnings volatility.